FLINT, Mich., Aug. 15, 2016 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) is now filling prescriptions for ZINBRYTA™ (daclizumab), which was recently approved by the Food and Drug Administration. ZINBRYTA is an interleukin-2 receptor-blocking antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS).
To learn more about Diplomat's multiple sclerosis program, click here.
"A relapse of any kind can cause a person to lose hope," said Gary Kadlec, Diplomat president. "For people with relapsing multiple sclerosis, ZINBRYTA has the potential to restore that hope and make life a little easier."
MS is an unpredictable, often disabling disease of the central nervous system; it interrupts the flow of information within the brain and between the brain and the rest of body. Symptoms include numbness, tingling, blindness, paralysis and cognitive difficulties. According to the National Multiple Sclerosis Society, most people with MS are diagnosed between ages 20 and 50, with at least twice as many women diagnosed as men.
ZINBRYTA is generally reserved for patients who have had an inadequate response to two or more therapies indicated for the treatment of MS.
ZINBRYTA is jointly manufactured by AbbVie, Inc., and Biogen, Inc. Click here for complete ZINBRYTA prescribing information.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended December 31, 2015 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit diplomat.is.